KCL-286 Could Rewrite Alzheimer’s Treatment | Science News

A breakthrough in Alzheimer’s research: scientists at King’s College London are fast-tracking an experimental drug, KCL-286, originally designed for spinal injuries, which now shows remarkable promise in treating the disease by repairing DNA damage and reducing brain inflammation—two early hallmarks of Alzheimer’s. Unlike current treatments that target amyloid or tau, this drug tackles multiple pathways at once, potentially offering a true disease-modifying therapy. With Phase 1 safety data already in hand, clinical trials for Alzheimer’s could begin sooner, offering hope for a faster, more effective treatment on the horizon. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/09ffc0f51a4994c2